Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy

NCT01265810 is registered in ClinicalTrials.gov with Impaqtt Foundation as lead sponsor.

NCT NCT01265810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01265810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy
Lead sponsor
Impaqtt Foundation
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
October 31, 2015
Enrollment
64 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors, hepatocellular carcinoma, oral complaints, renal cell carcinoma